SHC — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-06

• (a)Adjusted Net Income and Adjusted EBITDA are non-GAAP financial measures. For more information regarding our calculation of Adjusted Net Income and Adjusted EBITDA, including information about their limitations as tools for analysis and a reconciliation of net income, the most directly comparable …

• The following table compares our revenues by type for the three months ended June 30, 2026 to the three months ended June 30, 2025.

• Net revenues were $321.4 million for the three months ended June 30, 2026, an increase of $27.0 million, or 9.2%, as compared to the three months ended June 30, 2025. Excluding the impact of foreign currency exchange rates, net revenues for the three months ended June 30, 2026 increased approximatel…

• Service revenues increased $21.1 million, or 8.2%, to $278.3 million for the three months ended June 30, 2026 as compared to $257.2 million for the three months ended June 30, 2025. The growth in net service revenues was primarily driven by pricing in the Sterigenics and Nelson Labs segments, favora…

• Product revenues increased $6.0 million, or 16.0%, to $43.1 million for the three months ended June 30, 2026 as compared to $37.1 million for the three months ended June 30, 2025. The increase was driven by higher revenues from Co-60 in the Nordion segment due to the timing of reactor harvest schedu…

Text removed vs the prior filing · source: 10-Q · 2026-05-05

• Service revenues increased $17.7 million, or 7.9%, to $241.6 million for the three months ended March 31, 2026, as compared to $223.9 million for the three months ended March 31, 2025. Net service revenue growth was driven by favorable pricing in the Sterigenics and Nelson Labs segments, an increase…

• Product revenues increased $7.9 million, or 25.7%, to $38.4 million for the three months ended March 31, 2026, as compared to $30.6 million for the three months ended March 31, 2025. Favorable volume and mix at Nordion, which was primarily attributable to Co-60 harvest schedule timing, was the main …

• Cost of product revenues increased $2.7 million, or 23.4%, for the three months ended March 31, 2026, as compared to the three months ended March 31, 2025. The increase was primarily a result of higher volumes of Co-60 shipments, which resulted in increases in direct material and material transporta…

• On April 3, 2025, the Company agreed to resolve 97 pending and threatened EO claims in the State of Illinois. Pursuant to the terms of the term sheet, the Company agreed to pay $30.9 million to settle the claims.

• Interest expense, net decreased $6.1 million, or 15.0%, for the three months ended March 31, 2026, as compared to the three months ended March 31, 2025, primarily due to a lower variable interest rate on our Term Loan and a $75.0 million principal paydown. The weighted average interest rate on our o…

Text added vs the prior filing · source: 10-Q · 2026-08-06

• Legal Proceedings Not Described in Note 13 “Commitments and Contingencies” to Our Consolidated Financial Statements

• In addition to the matters that are identified in Note 13 “Commitments and Contingencies” to our consolidated financial statements for the three and six months ended June 30, 2026 contained in this Quarterly Report on Form 10-Q, and incorporated into this Item by reference, we report matters, if any…

Text removed vs the prior filing · source: 10-Q · 2026-05-05

• •Ethylene Oxide Tort Litigation – California, Georgia, Illinois and New Mexico;

• •Sotera Health Company Securities Litigation and Related Matters.

• Legal Proceedings Not Described in Note 13 “Commitments and Contingencies,” to Our Consolidated Financial Statements

• In addition to the matters identified in Note 13 “Commitments and Contingencies,” to our consolidated financial statements for the three months ended March 31, 2026 contained in this Quarterly Report on Form 10-Q, and incorporated into this item by reference, we report matters, if any, that constitu…